WeTrials
Recruiting

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

What is this study?

This early-stage study tests how safe it is to combine two targeted cancer drugs, neratinib and trastuzumab deruxtecan. Researchers want to find the best dose of this combination to help shrink solid tumors that have specific gene changes called HER2.

Who can participate?

You may be able to join if you have a solid tumor (such as advanced pancreatic cancer or other cancers) that cannot be removed by surgery or has spread, and tests show it has the HER2 gene change. There are rules about recent treatments you may have had, which the study team will review with you.

What will happen?

During the study, you will take the study medications and have regular check-ups, which include imaging scans, heart function tests, and providing small tissue or blood samples for research.

Where and when?

This study is currently recruiting participants and takes place in locations including Duarte and Irvine, California.

Key Points
  • 1Tests a combination of two targeted cancer therapies.
  • 2Designed for advanced solid tumors with HER2 gene changes.
  • 3Involves regular check-ups, imaging scans, and heart tests.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Malignant Solid NeoplasmUnresectable Pancreatic Adenocarcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.